Home
»
Market access and communications
»
Navigating the new normal for meetings – now and for the future
×
Register now for full access to all the content
Thank you for registering!
Error - something went wrong!
Other content in this Stream
Virtual meetings are easy, right?
Recommendations for navigating the "new normal" and how to prepare for the future.
EMA Guidance: Management of Clinical Trials - What it means for Patients?
A lay summary for patients participating in clinical trials
Putting the Pandemic in Plain Language
The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including anxiety, fear and social division, but what if we explored the new positive relationships...
CAR-T: How far have we come and where are we going?
In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days....
How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance
The UK national health technology assessment (HTA) body, the National Institute for Health and Clinical Excellence (NICE), made a long-awaited announcement last week: NICE has expanded the...
Interview with Paul Bridges, Head of R&A
If regulatory and payer landscapes are so different, then why bring the two worlds together?
Reimagining The Global Value Dossier - Part 6
A clear value strategy is key to the success of any product attempting to enter the healthcare market; defining the right strategy should lead to the perfect positioning for your product and...
Commercial and Regulatory Strategy Considerations for Biotech
Many critical and innovative new therapies today, including those for rare and untreated diseases, are in the biotech pipeline. In fact, today biotech represents more than 80 percent of the...
Use Real-World Evidence to Navigate From Regulatory Approval to Reimbursement Success
Use Real-World Evidence to Navigate From Regulatory Approval to Reimbursement Success
How to align your market access activities with your product value strategy
The value strategy (also termed value story) for your product should act as the cornerstone for all market access activities. The value strategy drives your market access planning, which...
Reimagining the Global Value Dossier - Part 4
Health Technology Assessment (HTA) agencies are increasingly demanding the inclusion of patient-relevant data in submission dossiers. It is evident that there is an effort to ensure...
Commercializing Gene and Cellular Therapy
Gene and cellular therapy manufacturing requires strict control in current Good Manufacturing Practice (cGMP) facilities. Designing a facility or finding a contract manufacturer to meet the...
Capturing the patient voice in market access communications
Patients have unique perspectives on their conditions that, when incorporated into value communications, can provide an authenticity and salience which would otherwise be lacking. Who knows...
Strengthen Your Product Value Story One Phase At A Time
Find out how to plan evidence generation for your value story!
